CTLA4 and Familial prostate cancer: As a recognized checkpoint in the immune system, CTLA-4 has been extensively investigated as an immunotherapeutic target for a variety of malignancies, including melanoma (68), prostate cancer (69), and hepatocellular cancer (70).